Propylthiouracil

Propylthiouracil

Systematic (IUPAC) name
6-propyl-2-sulfanylpyrimidin-4-one
Clinical data
AHFS/Drugs.com	monograph
MedlinePlus	a682465
Pregnancy category	D
Legal status	℞ (Prescription only)
Routes of administration	Oral
Pharmacokinetic data
Bioavailability	80%-95%
Metabolism	?
Biological half-life	2 hours
Excretion	?
Identifiers
CAS Number	51-52-5 Y
ATC code	H03BA02 (WHO)
PubChem	CID: 657298
IUPHAR/BPS	6650
DrugBank	DB00550 Y
ChemSpider	571424 Y
UNII	721M9407IY Y
KEGG	D00562 Y
ChEBI	CHEBI:8502 Y
ChEMBL	CHEMBL1518 Y
Chemical data
Formula	C7H10N2OS
Molecular mass	170.233 g/mol
SMILES S=C1N/C(=C\C(=O)N1)CCC
InChI InChI=1S/C7H10N2OS/c1-2-3-5-4-6(10)9-7(11)8-5/h4H,2-3H2,1H3,(H2,8,9,10,11) Y Key:KNAHARQHSZJURB-UHFFFAOYSA-N Y
(verify)

Propylthiouracil (PTU) or 6-n-propylthiouracil (PROP) is a thiouracil-derived drug used to treat hyperthyroidism (including Graves' disease) by decreasing the amount of thyroid hormone produced by the thyroid gland. Its notable side effects include a risk of agranulocytosis and aplastic anemia.

On 3 June 2009, the FDA published an alert "notifying healthcare professionals of the risk of serious liver injury, including liver failure and death, with the use of propylthiouracil." As a result, propylthiouracil is no longer recommended in non-pregnant adults and in children as the front line antithyroid medication.

It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system.[3]

History

It was approved by the US Food and Drug Administration in 1947.

Mechanism of action

Central

PTU inhibits the enzyme thyroperoxidase, which normally acts in thyroid hormone synthesis by oxidizing the anion iodide (I⁻) to iodine (I⁰), facilitating iodine's addition to tyrosine residues on the hormone precursor thyroglobulin. This is one of the essential steps in the formation of thyroxine (T4).

PTU does not inhibit the action of the sodium-dependent iodide transporter located on follicular cells' basolateral membranes. Inhibition of this step requires competitive inhibitors, such as perchlorate and thiocyanate.

Peripheral

PTU also acts by inhibiting the enzyme 5'-deiodinase (tetraiodothyronine 5' deiodinase), which converts T₄ to the active form T₃. (This is in contrast to methimazole, which shares propylthiouracil's central mechanism, but not its peripheral one.)

Pharmacokinetics

Administration is oral, with peak serum concentrations occurring in one hour, and actively concentrated to the thyroid gland. Depending on several patient variables, however, euthyroid status may not be achieved until 2–4 months after treatment initiation. Of note, the drug is approximately 70% protein-bound and significantly ionized at normal physiologic pH, while the antithyroid agent methimazole is substantially less protein bound. However both are equally transferred across the placenta.

The plasma half-life is one hour and is not altered appreciably by the thyroid status of the patient. Due to the concentration in the thyroid, however, dosing intervals may last 8 hours or longer. Less than 10% of the drug is excreted unchanged, with the remaining fraction undergoing extensive hepatic metabolism via glucuronidation.

Side effects

One possible side effect is agranulocytosis, a decrease of white blood cells in the blood. Symptoms and signs of agranulocytosis include infectious lesions of the throat, the gastrointestinal tract, and skin with an overall feeling of illness and fever. A decrease in blood platelets (thrombocytopenia) also may occur. Since platelets are important for the clotting of blood, thrombocytopenia may lead to problems with excessive bleeding. Side effects are suspected and the drug is sometimes discontinued if the patient complains of recurrent episodes of sore throat.

A more life-threatening side effect is sudden, severe, fulminant liver failure resulting in death or liver transplantation, which occurs in up to 1 in 10,000 people taking propylthiouracil. Unlike agranulocytosis which most commonly occurs in the first three months of therapy, this side effect may occur at any time during treatment.

Propylthiouracil is generally well tolerated, with side effects occurring in one of every 100 patients. The most common side effects are related to the skin, and include rash, itching, hives, abnormal hair loss, and skin pigmentation. Other common side effects are swelling, nausea, vomiting, heartburn, loss of taste, joint or muscle aches, numbness and headache, allergic reactions, and hair whitening.

Propylthiouracil in pregnancy

Propylthiouracil is classified as Drug Class D in pregnancy. Class D signifies there is positive evidence of human fetal risk. Maternal benefit may outweigh fetal risk in life-threatening situations. PTU is preferred over methimazole (which is also a class D) only in the first trimester of pregnancy and in woman who may become pregnant because of the increased risk of teratogenicity of Methimazole during critical organogenesis. In the second and third trimester, this risk is diminished and methimazole is preferred to avoid the risk of liver complications from PTU in the mother.

The primary effect on the fetus from transplacental passage of PTU is the production of a mild hypothyroidism when the drug is used close to term. This usually resolves within a few days without treatment. The hypothyroid state may be observed as a goiter in the newborn, and is the result of increased levels of fetal pituitary thyrotropin. The incidence of fetal goiter after PTU treatment in reported cases is approximately 12%.

Chemical synthesis

Propylthiouracil can be prepared from ethyl 3-oxohexanoate and thiourea.

See also

• Phenylthiocarbamide
• Supertaster
• TAS2R38
• Methylthiouracil